前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)活性蛋白
Active Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
FH3; HCHOLA3; NARC1; Hypercholesterolemia,Autosomal Dominant 3; Neural apoptosis-regulated convertase 1; Proprotein convertase 9; Subtilisin/kexin-like protease PC9
- 編號(hào)UAPE189Mu01
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點(diǎn)7.5
- 應(yīng)用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 708 ¥ 1770 ¥ 3540 ¥ 10620 ¥ 26550
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
Figure. SDS-PAGE
-
通過ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
活性實(shí)驗(yàn)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is one of nine mammalian serine proteases.It is secreted mostly by hepatocytes and to a lesser extent by the intestine, pancreas, kidney, adipose tissue, and vascular cells.PCSK9 can promote the degradation of LDL receptors in the liver, which in turn reduces the liver's ability to clear LDL-C from the bloodstream.Besides,Epidermal Growth Factor (EGF) has been identified as an interactor of PCSK9, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant mouse PCSK9 and recombinant human EGF. Briefly, PCSK9 was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to EGF-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PCSK9 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody for 1h at 37℃, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 μL stop solution to the wells and read at 450/630nm immediately. The binding activity of recombinant mouse PCSK9 and recombinant human EGF was shown in Figure 1, the EC50?for this effect is 0.111ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過一個(gè)月，-80°C不超過12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| UAPE189Mu01 | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPE189Mu02 | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| URPE189Mu01 | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAE189Mu01 | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)多克隆抗體 | IHC |
| UPAE189Mu02 | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)多克隆抗體 | WB; IHC; ICC; IP. |
| USEE189Mu | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| UAEE189Mu | 抗前蛋白轉(zhuǎn)化酶枯草溶菌素9抗體(Anti-PCSK9)檢測試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antibody Detection. |
| ULME189Mu | 前蛋白轉(zhuǎn)化酶枯草溶菌素9(PCSK9)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| Biological Trace Element Research | Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers [pubmed:28409410] |
| BASIC RESEARCH IN CARDIOLOGY | Autocrine effects of PCSK9 on cardiomyocytes [Pubmed: 33169229] |
| J Transl Med | Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans [33407555] |
| Metabolism | MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice [33775647] |
| Eur Rev Med Pharmacol Sci | Association of serum proprotein convertase Subtilisin/Kexin Type 9 (PCSK9) level with thyroid function disorders [34533801] |
| Clin Exp Hypertens | Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease [Pubmed:35502687] |
